EVRYSDI

Growth

risdiplam

NDAORALTABLET
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Survival of Motor Neuron 2 Splicing Modifiers

Pharmacologic Class:

Survival of Motor Neuron 2 Splicing Modifier

Clinical Trials (5)

NCT07444476Phase 3Not Yet Recruiting

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

Started Apr 2026
90 enrolled
Spinal Muscular Atrophy
NCT05861999Phase 4Recruiting

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Started Aug 2024
28 enrolled
Muscular Atrophy, Spinal
NCT05861986Phase 4Recruiting

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

Started May 2024
28 enrolled
Muscular Atrophy, Spinal
NCT05808764Phase 2Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

Started Apr 2024
10 enrolled
Muscular Atrophy, Spinal
NCT05386680Phase 3Completed

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

Started Jan 2023
27 enrolled
Spinal Muscular Atrophy

Loss of Exclusivity

LOE Date
Apr 15, 2041
184 months away
Patent Expiry
Apr 15, 2041
Exclusivity Expiry
Oct 3, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
9586955
Feb 8, 2033
SubstanceProduct
9969754
May 11, 2035
SubstanceProduct
U-1943
11827646
Jan 25, 2036
U-1943
12350273
Oct 1, 2038
U-1943
11534444
Oct 4, 2038
U-1943